Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Operating Margin (2020 - 2023)

Historic Operating Margin for Candel Therapeutics (CADL) over the last 4 years, with Q4 2023 value amounting to 228.43%.

  • Candel Therapeutics' Operating Margin rose 259038300.0% to 228.43% in Q4 2023 from the same period last year, while for Dec 2023 it was 1479.42%, marking a year-over-year increase of 265213800.0%. This contributed to the annual value of 1596.7% for FY2024, which is 1172800.0% down from last year.
  • According to the latest figures from Q4 2023, Candel Therapeutics' Operating Margin is 228.43%, which was up 259038300.0% from 1324.51% recorded in Q3 2023.
  • Candel Therapeutics' 5-year Operating Margin high stood at 1581.77% for Q1 2023, and its period low was 28987.1% during Q1 2022.
  • Over the past 4 years, Candel Therapeutics' median Operating Margin value was 17100.0% (recorded in 2021), while the average stood at 15193.5%.
  • In the last 5 years, Candel Therapeutics' Operating Margin plummeted by -170322600bps in 2021 and then soared by 305688700bps in 2023.
  • Quarter analysis of 4 years shows Candel Therapeutics' Operating Margin stood at 19758.06% in 2020, then fell by -26bps to 24967.74% in 2021, then dropped by -5bps to 26132.26% in 2022, then surged by 99bps to 228.43% in 2023.
  • Its Operating Margin was 228.43% in Q4 2023, compared to 1324.51% in Q3 2023 and 1487.42% in Q2 2023.